Integrated Diagnostics Holdings logo

IDHC - Integrated Diagnostics Holdings Share Price

$3.8 -0.1  -3.3%

Last Trade - 25/11/20

Mid Cap
Market Cap £441.4m
Enterprise Value £438.1m
Revenue £101.5m
Position in Universe 580th / 1800
Unlock IDHC Revenue
Relative Strength (%)
1m +0.10%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
860.2 1,015 1,171 1,514 1,921 2,226 2,175 2,718 +20.9%
+112.6 +9.1 +79.7 +43.6 +34.2 +1.8 -8.78 +31.3
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, IntegratedDiagnostics Holdings PLC revenues decreased 10% toEGP949.7M. Net income decreased 20% to EGP178.8M. Revenuesreflect a decrease in demand for the Company's products andservices due to unfavorable market conditions. Net incomealso reflects Administrative expenses increase of 24% toEGP103.3M (expense), Gains on sale of financial investmentsdecrease of 85% to EGP192K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for IDHC
Graphical History


IDHC Revenue Unlock IDHC Revenue

Net Income

IDHC Net Income Unlock IDHC Revenue

Normalised EPS

IDHC Normalised EPS Unlock IDHC Revenue

PE Ratio Range

IDHC PE Ratio Range Unlock IDHC Revenue

Dividend Yield Range

IDHC Dividend Yield Range Unlock IDHC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IDHC EPS Forecasts Unlock IDHC Revenue
Profile Summary

Integrated Diagnostics Holdings plc is an integrated diagnostics services provider in Egypt. The Company operates in three geographic areas: Egypt, Sudan and Jordan. The Company provides over 1,000 diagnostic services ranging from basic tests to molecular tests for hepatitis and specialized deoxyribonucleic acid (DNA) tests to patients, and operates approximately 310 branches. The Company offers a range of services, such as Immunology, Radiology, Hematology, Endocrinology, Molecular Biology, Cytogenetics, Hatopathology and Microbiology. The Company's core brands include Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan, and Ultralab and Al Mokhtabar Sudan in Sudan. The Company also operates the Medical Genetics Centre brand in Egypt. Its Al Mokhtabar medical testing and diagnostic center provides services, including radiological tests, a center for allergy, a unit for nutritional advice, pre-employments tests, medical examination in different fields and checkup packages.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated December 4, 2014
Public Since May 6, 2015
No. of Shareholders: n/a
No. of Employees: 5,440
Sector Healthcare
Industry Healthcare Providers & Services
Exchange London Stock Exchange (Full)
Shares in Issue 150,000,000
Free Float (0.0%)
Eligible for
IDHC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IDHC
Upcoming Events for IDHC
Frequently Asked Questions for Integrated Diagnostics Holdings
What is the Integrated Diagnostics Holdings share price?

As of 25/11/20, shares in Integrated Diagnostics Holdings are trading at $3.8, giving the company a market capitalisation of £441.4m. This share price information is delayed by 15 minutes.

How has the Integrated Diagnostics Holdings share price performed this year?

Shares in Integrated Diagnostics Holdings are currently trading at $3.8 and the price has moved by -14.1% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Integrated Diagnostics Holdings price has moved by -1.86% over the past year.

What are the analyst and broker recommendations for Integrated Diagnostics Holdings?

Of the analysts with advisory recommendations for Integrated Diagnostics Holdings, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Integrated Diagnostics Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Integrated Diagnostics Holdings next release its financial results?

Integrated Diagnostics Holdings is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Integrated Diagnostics Holdings dividend yield?

The Integrated Diagnostics Holdings dividend yield is 4.91% based on the trailing twelve month period.

Does Integrated Diagnostics Holdings pay a dividend?

Last year, Integrated Diagnostics Holdings paid a total dividend of 3.01, and it currently has a trailing dividend yield of 4.91%. Looking ahead, Integrated Diagnostics Holdings has not announced an ex-dividend date yet.

When does Integrated Diagnostics Holdings next pay dividends?

Integrated Diagnostics Holdings has yet to annouce their ex-dividend date. The historic dividend yield on Integrated Diagnostics Holdings shares is currently 4.91%.

How do I buy Integrated Diagnostics Holdings shares?

To buy shares in Integrated Diagnostics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Integrated Diagnostics Holdings?

Shares in Integrated Diagnostics Holdings are currently trading at $3.8, giving the company a market capitalisation of £441.4m.

Where are Integrated Diagnostics Holdings shares listed? Where are Integrated Diagnostics Holdings shares listed?

Here are the trading details for Integrated Diagnostics Holdings:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: IDHC
What kind of share is Integrated Diagnostics Holdings?

Based on an overall assessment of its quality, value and momentum, Integrated Diagnostics Holdings is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Integrated Diagnostics Holdings share price forecast 2020?

Shares in Integrated Diagnostics Holdings are currently priced at $3.8. At that level they are trading at 27.18% discount to the analyst consensus target price of 0.00.

Analysts covering Integrated Diagnostics Holdings currently have a consensus Earnings Per Share (EPS) forecast of 3.107 for the next financial year.

How can I tell whether the Integrated Diagnostics Holdings share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Integrated Diagnostics Holdings. Over the past six months, the relative strength of its shares against the market has been 13.54%. At the current price of $3.8, shares in Integrated Diagnostics Holdings are trading at 7.05% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Integrated Diagnostics Holdings PE Ratio?

The Integrated Diagnostics Holdings PE ratio based on its reported earnings over the past 12 months is 19.74. The shares are currently trading at $3.8.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Integrated Diagnostics Holdings?

Integrated Diagnostics Holdings's management team is headed by:

Anthony St John - NEC
Hend El Sherbini - CEO
Hussein Choucri - NID
James Nolan - NID
Dan Olsson - NID
Richard Phillips - NED
Omar Bedewy - CFO
Who are the major shareholders of Integrated Diagnostics Holdings?

Here are the top five shareholders of Integrated Diagnostics Holdings based on the size of their shareholding:

HENA Holdings, Ltd. Corporation
Percentage owned: 25.5% (38.2m shares)
Actis LLP Private Equity
Percentage owned: 21% (31.5m shares)
HSBC Global Asset Management (UK) Limited Investment Advisor/Hedge Fund
Percentage owned: 8.51% (12.8m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 4.35% (6.53m shares)
T. Rowe Price International (UK) Ltd. Investment Advisor/Hedge Fund
Percentage owned: 4.01% (6.01m shares)
Similar to IDHC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.